Navigation Links
The MDS Foundation supports the FDA's decision to expand vidaza label to include survival data
Date:8/25/2008

Crosswicks, NJ (August 22, 2008) The Myelodysplastic Syndromes (MDS) Foundation supports the decision by the U.S. Food & Drug Administration (FDA) to extend the label for VIDAZA (azacitidine) to include data from the AZA-001 clinical trial. Results from the trial found that azacitidine is the only agent which has been shown to extend survival in MDS patients.

Data from the AZA-001 trial was recently presented at this year's American Society of Clinical Oncology (ASCO) Annual Meeting and found that azacitidine nearly doubled the two-year survival rate for higher-risk MDS patients compared to conventional care regimens (CCR) with a mean survival of 24.5 months compared to 15 months for patients who received CCR.

"We are extremely encouraged by the results of the AZA-001 trial which for the first time showed that survival could be extended for patients with higher-risk MDS," said Kathy Heptinstall, Operating Director of the Myelodysplastic Syndromes Foundation, "Roughly 30 percent of patients diagnosed with MDS will progress to acute myeloid leukemia (AML), but treatment with VIDAZA significantly delays this progression. VIDAZA not only has great survival data in MDS, but can also prevent progression to AML."

Results from the trial also showed that azacitidine reduced the need for blood transfusions in higher-risk MDS patients with nearly half (45 percent) of patients who were transfusion dependent at the start of the trial achieving transfusion independence.

Additionally, azacitidine was shown to delay the progression of MDS to acute myeloid leukemia (AML). Roughly 30 percent of patient diagnosed with MDS will progress to AML. The delay in progression is especially significant because patients with MDS are typically over the age of 65. According to the National Institute of Health, in this patient group, the average 5-year survival rate after diagnosis with AML is only approximately four percent.

MDS is a primary neoplasm of the bone marrow that is more prevalent than any of the leukemias. MDS affects the function of blood cells, either red blood cells, white blood cells or platelets. The incidence of MDS is underestimated.


'/>"/>

Contact: Kathy Heptinstall
800-637-0839
Weber Shandwick Worldwide
Source:Eurekalert

Related biology news :

1. New York Stem Cell Foundation announces third annual Translational Stem Cell Research Conference
2. Michael J. Fox Foundation PD Therapeutics Conference
3. Michael J. Fox Foundation Funds $1.1 Million for Cutting-edge Approaches to Parkinsons Disease
4. W.M. Keck Foundation grant funds reproductive science research
5. W.M. Keck Foundation announces 2008 class of Distinguished Young Scholars in Medical Research
6. Michael J. Fox Foundation awards $2.4M for validation of therapeutic targets for Parkinsons
7. Glenn Foundation for Medical Research commits $5 million to study aging
8. BBVA Foundation Awards for Biodiversity Conservation
9. The Parkinsons Disease Foundation awards $950,000 in seed grants
10. The AGA Foundation invests in gastroenterologys future
11. European Science Foundation aims to strengthen regenerative medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/9/2016)... leader in attendance control systems is proud to announce the introduction of fingerprint attendance ... the right employees are actually signing in, and to even control the opening of ... ... ... Photo - ...
(Date:6/2/2016)... The Department of Transport Management (DOTM) of ... Dollar project, for the , Supply and Delivery ... IT Infrastructure , to Decatur ... Identity Management Solutions. Numerous renowned international vendors participated in the ... was selected for the most compliant and innovative solution. The ...
(Date:5/24/2016)... , May 24, 2016 Ampronix facilitates superior patient care by providing ...  3D medical LCD display is the latest premium product recently added to the range ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young ... cancer. Members of the Class of 2016 were selected from a pool of ... More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case ... Denmark detail how a patient who developed lymphedema after being treated for breast cancer ... could change the paradigm for dealing with this debilitating, frequent side effect of cancer ...
Breaking Biology Technology: